Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012
CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


Stereotactic Ablative Radiotherapy achieves better overall survival than surgery for early lung cancer
Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care -- invasive surgery -- according to research from a phase III randomized international study from The University of Texas MD Anderson Cancer Center.

Experimental immunotherapy shows high response rate in advanced lung cancer
An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer.

ASTRO issues guideline on definitive and adjuvant RT for locally advanced non-small cell lung cancer
The American Society for Radiation Oncology (ASTRO) is issuing a new guideline, "Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline."

Multiple types of resistance to new lung cancer drug identified
After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

Profiling approach to enable right lung cancer treatment match
Manchester researchers have tested a new way to genetically profile lung cancer samples, potentially allowing doctors to more easily identify the most appropriate treatment for patients.

Pneumonectomy or lobectomy?
For patients in the early stage of non-small cell lung cancer, surgical resection yields optimal outcomes. Prior investigations have shown that different resection procedures have very different outcomes, with pneumonectomy associated with three-fold higher mortality than other resection types.

MD Anderson study points to potential new lung cancer therapy
New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

Driver of non-small cell lung cancer, FGFR1, also in 23 percent of small cell lung cancer
Significant new treatments are available or in clinical trials for non-small cell lung cancer. The same explosion in treatment options is not true for the disease's cousin, small cell lung cancer, the less common and more aggressive form of the disease.

Anti-fungal drug shows promise as potential new cancer treatment
A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience.

Socioeconomic factors affect odds of death after a lung cancer operation
People with limited education and low income have higher odds of death within 30 days after undergoing an operation for lung cancer than those who are more educated and financially better off.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers

RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers


Worldwide, approximately one and a half million new cases of lung cancer are diagnosed each year, and about 85% of lung cancer are non-small cell lung cancer (NSCLC). As the molecular pathogenesis underlying NSCLC is understood, new molecular targeting agents can be developed. However, current therapies are not sufficient to cure or manage the patients with distant metastasis, and novel strategies are necessary to be developed to cure the patients with advanced NSCLC.

RNA interference (RNAi) is a phenomenon of sequence-specific gene silencing in mammalian cells and its discovery has lead to its wide application as a powerful tool in post-genomic research. Recently, short interfering RNA (siRNA), which induces RNAi, has been experimentally introduced as a cancer therapy and is...

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. OPDIVO (nivolumab) is also indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. OPDIVO (nivolumab) treat your melanoma or lung cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to...

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)
by Marc S. Sabatine MD (Author)


Prepared by residents and attending physicians at Massachusetts General Hospital, the 5th edition of Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine provides key clinical information and solutions to common problems faced in the practice of internal medicine.Designed to fit in a pocket, this 6-ring looseleaf binder tackles the diagnosis and treatment of the most common disorders in cardiology, pulmonary medicine, gastroenterology, nephrology, hematology-oncology, infectious diseases, endocrinology, rheumatology, and neurology.Bulleted lists combined with tables and algorithms allow busy clinicians to find the information they need rapidly. A 16-page color insert displays classic normal and abnormal radiographs, CT scans, echocardiograms, peripheral blood...

Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX Examination, 3e

Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX Examination, 3e
by Linda A. LaCharity PhD RN (Author), Candice K. Kumagai RN MSN (Author), Barbara Bartz RN MN CCRN (Author)


The only NCLEX review book on the market with a focus on prioritization, delegation, and patient assignment - just like the current NCLEX Examination itself! Using a unique simple-to-complex approach, Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX® Examination, 3rd Edition establishes your foundational knowledge in management of care, then provides exercises of increasing difficulty to help you build confidence in your prioritization, delegation, and patient assignment skills.UNIQUE! Emphasis on the NCLEX Examination’s management-of-care focus addresses the heavy emphasis on prioritization, delegation, and patient assignment in the current NCLEX Examination (17-23% of the 2013 NCLEX-RN Exam).UNIQUE! Three-part organization establishes foundational...

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay


DNA fluorescence in situ hybridization (FISH) technology is used to study chromosomal and genomic changes in fixed cell suspensions and tissue block preparations. The technique is based on specific hybridization of small labeled DNA fragments, the probes, to complementary sequences in a target DNA molecule. Demand for FISH assays in formalin-fixed, paraffin-embedded tissues has been increasing, mainly in conditions in which diagnosis is not achieved in cell smears or tissue imprints, such as solid tumors. Moreover, the development of molecular targeted therapies in oncology has expanded the applicability of tests to predict sensitivity or resistance to these agents. The efficient use of tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) as therapeutical agents...

First Aid for the USMLE Step 2 CK, Eighth Edition (First Aid for the USMLE Step 2: Clinical Knowledge)

First Aid for the USMLE Step 2 CK, Eighth Edition (First Aid for the USMLE Step 2: Clinical Knowledge)
by Tao Le (Author), Vikas Bhushan (Author), Nathan Skelley (Author)


An indispensable high-yield review for the USMLE Step 2 CK! The eighth edition of First Aid for the USMLE Step 2 CK is written by medical students who successfully passed the exam and reviewed by top faculty. The result is proven information and strategies that maximize your study time and deliver the results you want! Features:
Thousands of must-know facts that summarize frequently tested topics Completely updated based on feedback from students who passed 120+ photographs similar to those on the exam Full-color design includes numerous clinical images Rapid Review section for last-minute cramming Updated ratings of Step 2 CK review resources

Step-Up to Medicine (Step-Up Series)3rd EDITION

Step-Up to Medicine (Step-Up Series)3rd EDITION
by Steven S. Agabegi MD (Author), Elizabeth Agabegi MD (Author)


Step-Up to Medicine is your lifeline for the clinical years of medical school. This book was originally written by third-year medical students searching for the perfect review book—not finding it on the market, they wrote it themselves! Now in its third edition, Step-Up to Medicine boils down the full scope of tested pathology in a single ingenious tool. Each element is tailored for immediate content absorption, and an all-new, full-color interior differentiate elements for even faster, more efficient review. And, Step-Up to Medicine, third edition provides two types of self-assessment—the kinds of questions you will ask yourself as a clinician plus USMLE-style practice questions. This review book gives you just the Step-Up to the medicine clerkship, accompanying shelf exams, and...

miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc

miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc


MicroRNAs are important gene regulators that potentially play a profound role in tumorigenesis. Increasing evidence indicates that miR-145 is a tumor suppressor capable of inhibiting breast and colon cancer cell growth both in vitro and in vivo. However, the biological function of miR-145 in non-small cell lung cancer (NSCLC) is largely unknown. In colon cancer cells, c-Myc is a confirmed direct target for miR-145. The aim of this work was to investigate the effect of miR-145 and c-Myc on proliferation of NSCLC cells, using the NSCLC cell lines A549 and H23 as models. We determined the expression level of miR-145 in tumor tissues relative to adjacent non-tumor tissues, and in NSCLC cell lines relative to non-malignant lung cells. Downregulation of miR-145 was seen in tumor tissues and the...

Medifocus Guidebook on: Non-Small Cell Lung Cancer

Medifocus Guidebook on: Non-Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

© 2015 BrightSurf.com